JMP reiterates Oscient market outperform rating

Oscient Pharmaceuticals Corp. was reiterated by JMP Securities analyst Adam Cutler at a market outperform rating with a $3 price target. Factive prescriptions for the week ended Oct. 21 were 4,419, representing 0.70% of weekly prescriptions for the quinolone class of antibiotics. This compares to 4,084 total prescriptions the previous week. Prescriptions for the testosterone gel also were up slightly from the previous week. Shares of the Waltham, Mass.-based pharmaceutical company were unchanged at $1.75 on volume of 285,061 shares versus the three-month running average of 713,511 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.